Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa.
暂无分享,去创建一个
[1] R. Fischer,et al. Effects of inhaled MP-376 (aeroquin, levofloxacin inhalation solution) on lung function in stable cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa (PA) lung infection , 2010 .
[2] D. C. Griffith,et al. Effect of oxygen limitation on the in vitro activity of levofloxacin and other antibiotics administered by the aerosol route against Pseudomonas aeruginosa from cystic fibrosis patients. , 2010, Diagnostic microbiology and infectious disease.
[3] D. Sanders,et al. Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis , 2010, Pediatric pulmonology.
[4] D. C. Griffith,et al. In Vitro Pharmacodynamics of Levofloxacin and Other Aerosolized Antibiotics under Multiple Conditions Relevant to Chronic Pulmonary Infection in Cystic Fibrosis , 2009, Antimicrobial Agents and Chemotherapy.
[5] D. Touw,et al. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus. , 2009, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[6] D. Geller,et al. New aerosol delivery devices for cystic fibrosis. , 2009, Respiratory care.
[7] A. Quittner,et al. Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. , 2009, Chest.
[8] R. Gibson,et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. , 2009, Chest.
[9] R. Gibson,et al. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. , 2008, American journal of respiratory and critical care medicine.
[10] W. Morgan,et al. Trends in the clinical characteristics of the U.S. cystic fibrosis patient population from 1995 to 2005 , 2008, Pediatric pulmonology.
[11] C. Goss,et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. , 2007, American journal of respiratory and critical care medicine.
[12] A. Quittner,et al. A multi-method assessment of treatment adherence for children with cystic fibrosis. , 2006, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[13] Angela Lee,et al. Pharmacodynamics of Levofloxacin against Pseudomonas aeruginosa with Reduced Susceptibility Due to Different Efflux Pumps: Do Elevated MICs Always Predict Reduced In Vivo Efficacy? , 2006, Antimicrobial Agents and Chemotherapy.
[14] R. Gibson,et al. Pathophysiology and management of pulmonary infections in cystic fibrosis. , 2003, American journal of respiratory and critical care medicine.
[15] Michael H. Miller,et al. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. , 2003, The Journal of clinical investigation.
[16] C. M. Bowman,et al. The long-term use of inhaled tobramycin in patients with cystic fibrosis. , 2002, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[17] J. Emerson,et al. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis , 2002, Pediatric pulmonology.
[18] B. Ramsey,et al. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. , 2002, Chest.
[19] J. Emerson,et al. Defining a pulmonary exacerbation in cystic fibrosis. , 2001, The Journal of pediatrics.
[20] J. Carlin,et al. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. , 2001, The Journal of pediatrics.
[21] M. Hodson,et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. , 2000, The European respiratory journal.
[22] B. Ramsey,et al. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. , 1999, The Journal of infectious diseases.
[23] M S Pepe,et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. , 1999, The New England journal of medicine.
[24] G L Drusano,et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. , 1998, JAMA.
[25] P. J. Byard,et al. Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection. , 1995, Journal of clinical epidemiology.
[26] A. Bush,et al. Effects of Pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis , 1995, Pediatric pulmonology.
[27] J L Hankinson,et al. Spirometric reference values from a sample of the general U.S. population. , 1999, American journal of respiratory and critical care medicine.